drugset / Trial / NCT06916156
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
NaSingle-groupOpen-labelOther
Summary
This is an open-label, non-randomized, single-center, repeated i.v. doses, Phase 1 trial to evaluate the pharmacokinetics, safety, and tolerability of a combination of MEM-ANT3310 in healthy adult female and male participants who will undergo a single bronchoalveolar lavage (BAL) via a standardized fiberoptic bronchoscopy to evaluate and compare the pharmacokinetics characteristics of ANT3310 and meropenem (MEM) in plasma and epithelial lining luid (ELF).
Timeline
- Start
- 2025-04-28
- Primary completion
- 2025-08-14
- Completion
- 2025-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANT3310 | Unknown | — | Intravenous |
| Subject | Meropenem | Small molecule | — | Intravenous |
Indications
No indication recorded.